New PET/CT scan for ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new imaging method that uses a special tracer (like a dye) to light up ovarian cancer cells on a PET/CT scan. It aims to help doctors see the cancer more clearly and to check whether treatment is working, which could lead to better care for people with advanced or recurrent ovarian cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have ovarian cancer that is either newly diagnosed at stage IV or has come back for the first time.
- Your overall health is stable enough: blood counts, liver, and kidney function are within normal limits.
- You are expected to live at least 6 more months.
- You have at least one tumor that can be measured on a scan.
- If you could become pregnant, you must not be pregnant (negative test within 7 days) and agree to use effective birth control during the study and for 3-6 months after the last scan.
- You must be able to lie still for 30 minutes and not have severe allergies to the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses two types of PET/CT scans (68Ga-FAPI-46 and 18F-FDG) to look for any returning ovarian cancer. The goal is to find recurrence early so you and your doctor can plan the next steps.
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
This trial studies how well medical imaging (especially MRI) can help predict outcomes and improve diagnosis in people newly diagnosed with certain gynecologic cancers. It may help doctors make more accurate treatment decisions by comparing imaging results to the final cancer type and stage.
This study tests a drug called mirvetuximab soravtansine (MIRV) for women with ovarian, fallopian tube, or primary peritoneal cancer that has not responded to recent treatment. The drug targets a specific protein (FRα) found on some cancer cells, and the study will see how well it works in real-world settings.
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.